Pharmacy benefit managers (PBMs) were in the news in 2022, and Managed Healthcare Executive®’s coverage of PBMs garnered a great deal of attention.
Smaller and midsize pharmacy benefit managers are taking on Optum Rx, CVS Caremark and Express Scripts. They say they have better technology and are more transparent about their pricing.
The Big Three all set up group purchasing organizations recently, but some industry observers question the timing of the move and who will benefit.
EmsanaRx, a pharmacy benefit manager launched by the Purchaser Business Group on Health, started operations in January 2022
Agenda includes sessions on overall trends in the pharmacy benefit management industry, digital therapeutics and biosimilars.
The president of CVS Caremark discusses the PBM industry’s reputation, list prices and rebates.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More
Drugs to Watch: Mental Health Conditions
April 11th 2024The FDA is reviewing two novel therapies: a psychedelic-assisted therapy for PTSD with a target action date of Aug. 11, 2024, and therapy for schizophrenia that does not directly block dopamine receptors with an action date of Sept. 26, 2024.
Read More